Although different studies suggest that high tumor PD-L1 expression is pivotal for successful cancer immunotherapy [11,15,16], some patients with high PD-L1 expression do not experience benefit from immune checkpoint inhibitors [17], while tumor responses in patients with low or absent tumor PD-L1 expression may be found [18,19]. Here, CD274 is linked to neoplasm.